A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors
A phase 1/2 trial of AST-001 in pancreatic ductal adenocarcinoma, run by Ascentawits Pharmaceuticals, Ltd, now recruiting.
Overview
A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06245330 by Ascentawits Pharmaceuticals, Ltd, with 180 participants planned, started 2022-07-07 and due to reach its primary completion in 2027-08-31. Interventions recorded: AST-001.
Similar pages
not linked directly; found by shared links- TrialA Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
Shares Ascentawits Pharmaceuticals and the tag pipeline.
- TrialGlufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialA Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialFOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialAcoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialThe Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialRecombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.